Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

Sponsor
Institut Curie
Study ID
NCT07111117
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
365 Days - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • 18F-MFBG PET/CT imaging — PROCEDURE
    Participants will receive the 18F-MFBG tracer and undergo a PET/CT imaging.

Study Details

The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.

Key Dates

Start date
Mar 1, 2026
Status verified
Jul 2025
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 18F-MFBG PET/CT imaging
    Participants will receive the 18F-MFBG tracer and undergo a PET/CT imaging.

Primary Outcome Measure

Diagnostic agreement between 18F-MFBG PET/CT (new procedure) and 123I-MIBG scintigraphy (gold standard) [ Time Frame: The day of the PET/CT procedure ]

Central Contacts

Related Studies